Paradigm Biopharmaceuticals
(ASX) PAR
Paradigm Biopharmaceuticals Financials at a Glance
Market Cap
$102.33M
Revenue (TTM)
$143.07K
Net Income (TTM)
$51.71M
EPS (TTM)
$-0.09
P/E Ratio
-2.58
Dividend
$0.00
Beta (Volatility)
-0.19 (Low)
Dividend
$0.00
Beta (Volatility)
-0.19 (Low)
Price
$0.23
Volume
766,894
Open
$0.23
Price
$0.23
Volume
766,894
Open
$0.23
Previous Close
$0.23
Daily Range
$0.23 - $0.23
52-Week Range
$0.23 - $0.48
Dividend
$0.00
Beta (Volatility)
-0.19 (Low)
Price
$0.23
Volume
766,894
Open
$0.23
Previous Close
$0.23
Daily Range
$0.23 - $0.23
52-Week Range
$0.23 - $0.48
PAR News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Paradigm Biopharmaceuticals
Industry
Biotechnology
Sector
Health CareCEO
Paul John Rennie
Website
www.paradigmbiopharma.comHeadquarters
Melbourne, VIC 3000, AU
PAR Financials
Key Financial Metrics (TTM)
Gross Margin
-2%
Operating Margin
-638%
Net Income Margin
-596%
Return on Equity
-180%
Return on Capital
-6%
Return on Assets
-2%
Earnings Yield
-38.76%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$102.33M
Shares Outstanding
444.91M
Volume
766.89K
Short Interest
0.00%
Avg. Volume
1.12M
Financials (TTM)
Gross Profit
$19.89K
Operating Income
$22.89M
EBITDA
$25.25M
Operating Cash Flow
$15.99M
Capital Expenditure
$5.00
Free Cash Flow
$15.99M
Cash & ST Invst.
$16.82M
Total Debt
$5.48K
Paradigm Biopharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$25.15K
N/A
Gross Profit
$51.17K
+30.3%
Gross Margin
-2.03%
N/A
Market Cap
$102.33M
N/A
Market Cap/Employee
N/A
N/A
Employees
N/A
N/A
Net Income
$23.24M
+52.5%
EBITDA
$21.76M
+56.5%
Quarterly Fundamentals
Net Cash
$13.65M
-59.0%
Accounts Receivable
$6.31M
-15.0%
Inventory
$0.00
N/A
Long Term Debt
$873.62K
+393.5%
Short Term Debt
$137.95K
-39.1%
Return on Assets
-1.56%
N/A
Return on Invested Capital
-5.90%
N/A
Free Cash Flow
$0.00
+100.0%
Operating Cash Flow
$19.65M
+61.5%